Calcium-channel modulators for cardiovascular disease

Expert Opinion on Emerging Drugs

Volumn 11, Issue 1, 2006, Pages 49-73

  Godfraind, Théophile ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Angina pectoris; Atherosclerosis; Calcium antagonists; Calcium channel blockers; Hypertension; Stroke

Indexed keywords

2 AMINO 5 CYANO 1,4 DIHYDRO 6 METHYL 4 (3 PHENYL 5 QUINOLINYL) 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; AMLODIPINE PLUS BENAZEPRIL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CHLORTALIDONE; CINNARIZINE; DELAPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FELODIPINE; HYDROCHLOROTHIAZIDE; ISRADIPINE; LACIDIPINE; MANIDIPINE; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PLACEBO; RAMIPRIL; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANGINA PECTORIS; ANIMAL TISSUE; ATHEROSCLEROSIS; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; HYPERTENSION; NONHUMAN; REVIEW; RISK FACTOR; STROKE; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; RANDOMIZED CONTROLLED TRIALS; VASODILATION;

EID: 33645129041     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.11.1.49     Document Type: Review

References (203)

1. GODFRAIND T: Calcium channel blockers. Birkhaäuser Verla, Basel, Switzerland (2004).
2. GODFRAIND T, MILLER R, WIBO M: Calcium antagonism and calcium entry blockade. Pharmacol. Rev. (1986) 38(4):321-416.
3. 2+ channels. Trends Pharmacol. Sci. (1991) 12:349-354.
4. ERTEL EA, CAMPBELL KP, HARPOLD MM et al.: Nomenclature of voltage-gated calcium channels. Neuron (2000) 25(3):533-535.
5. 2+ channel antagonists. Trends Pharmacol. Sci. (1992) 13(6):256-262.
6. 2+ channel. Proc. Natl. Acad. Sci. USA (1997) 94(26):14906-14911.
7. 2+ channels. Ann. Rev. Cell Dev. Biol. (2000) 16:521-555.
8. MOOSMANG S, LENHARDT P, HAIDER N, HOFMANN F, WEGENER JW: Mouse models to study L-type calcium channel function. Pharmacol. Ther. (2005) 106(3):347-355.
9. 2+ channels in cardiac pacemaker activity. Proc. Natl. Acad. Sci. USA (2003) 100(9):5543-5548.
10. SPEDDING M, PAOLETTI R: Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol. Rev. (1992) 44(3):363-376.
11. SCHUSTER A, LACINOVA L, KLUGBAUER N, ITO H, BIRNBAUMER L, HOFMANN F: The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines. EMBO J. (1996) 15(10):2365-2370.
12. HOCKERMAN GH, JOHNSON BD, ABBOTT MR, SCHEUER T, CATTERALL WA: Molecular determinants of high affinity phenylalkylamine block of L-type calcium channels in transmembrane segment IIIS6 and the pore region of the α1-subunit. J. Biol. Chem. (1997) 272(30):18759-18765.
13. 2+) channels. Mol. Pharmacol. (2000) 58(6):1264-1270.
14. HOFMANN F, LACINOVA L, KLUGBAUER N: Voltage-dependent calcium channels: from structure to function. Rev. Physiol. Biochem. Pharmacol. (1999) 139:33-87.
15. 2+) channels. Cell Physiol. Biochem. (1999) 9(4-5):242-269.
16. VUAGNAT A, GIACCHE M, HOPKINS PN et al.: Blood pressure response to angiotensin II, low-density lipoprotein cholesterol and polymorphisms of the angiotensin II type 1 receptor gene in hypertensive sibling pairs. J. Mol. Med. (2001) 79(4):175-183.
17. WILLIAMS RR, HUNT SC, HOPKINS PN et al.: Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA (1988) 259(24):3579-3586.
18. BLACK HR, ELLIOTT WJ, GRANDITS G et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 289(16):2073-2082.
19. AGARWAL A, WILLIAMS GH, FISHER ND: Genetics of human hypertension. Trends Endocrinol. Metab. (2005) 16(3):127-133.
20. WILLIAMS GH: Genetic factors associated with volume-sensitive hypertension. Mol. Cell Endocrinol. (2004) 217(1-2):41-44.
21. NABER CK, SIFFERT W: Genetics of human arterial hypertension. Minerva Med. (2004) 95(5):347-356.
22. IZZO J: Hypertension Primer. Third ed. American Heart Association, Dallas, Texas, USA (2003).
23. CORVOL P, SOUBRIER F, JEUNEMAITRE X: Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension. Pathol. Biol. (Paris) (1997) 45(3):229-239.
24. BIANCHI G, FERRARI P, STAESSEN JA: Adducin polymorphism: detection and impact on hypertension and related disorders. Hypertension (2005) 45(3):331-340.
25. KEARNEY PM, WHELTON M, REYNOLDS K, MUNTNER P, WHELTON PK, HE J: Global burden of hypertension: analysis of worldwide data. Lancet (2005) 365(9455):217-223.
26. CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 42(6):1206-1252.
27. EUROPEAN SOCIETY OF HYPERTENSION-EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES COMMITTEE: 2003 European Society Of Hypertension-European Society Of Cardiology Guidelines For The Management Of Arterial Hypertension. J. Hypertem. (2003) 21(6):1011-1053.
28. ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP. THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA (2002) 288(23):2981-2997.
29. ZANCHETTI A, MANCIA G: The ALLHAT trial: a verdict or a challenge? J. Hypertens. (2003) 21(2):223.
30. BATH P, CHALMERS J, POWERS W et al.: International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J. Hypertens. (2003) 21(4):665-672.
31. ZANCHETTI A: Emerging data on calcium-channel blockers: the COHORT study. Clin. Cardiol. (2003) 26(2Suppl. 2):II17-II20.
32. FURBERG CD: A new era in hypertension research: discussing the findings of ALLHAT. Curr. Control Trials Cardiovasc. Med. (2001) 2(6):249-250.
33. KAPLAN NM: The meaning of ALLHAT. J. Hypertens. (2003) 21(2):233-234.
34. MCINNES GT: ALLHAT: a saga of missed opportunities. J. Hum. Hypertens. (2003) 17(6):373-377.
35. ALDERMAN MH: ALLHAT and beyond. Am. J. Hypertens. (2003) 16(6):512-514.
36. MOSER M: Results of ALLHAT: is this the final answer regarding initial antihypertensive drug therapy? Arch. Intern. Med. (2003) 163(11):1269-1273.
37. FURBERG CD, PSATY BM, MEYER JV: Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation (1995) 92(5):1326-1331.
38. STAESSEN JA, WANG JG, THIJS L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (2001)358(9290):1305-1315.
39. STAESSEN JA, WANG JG, THIJS L: Calcium-channel blockade and cardiovascular prognosis: recent evidence from clinical outcome trials. Am. J. Hypertens. (2002) 15(7 Pt 2):85S-93S.
40. OPIE LH, SCHALL R: Evidence-based evaluation of calcium channel blockers for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J. Coll. Cardiol. (2002) 39(2):315-322.
41. OPIE LH: Calcium channel biockers in hypertension: reappraisal after new trials and major meta-analyses. Am. J. Hypertens. (2001) 14(10):1074-1081.
42. HENRY PD, BENTLEY KI: Suppression of atherogenesis in cholesterol-fed rabbit treated with nifedipine. J. Clin. Invest. (1981)68(5):1366-1369.
43. LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W, HECKER H, JOST S, DECKERS JW: Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet (1990) 335(8698):1109-1113.
44. LICHTLEN PR, HUGENHOLTZ PG, RAFFLENBEUL W et al.: Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy). Cardiovasc. Drugs Ther. (1990) 4(Suppl. 5):1047-1068.
45. ZANCHETTI A, BOND MG, HENNIG M et al.: Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 106(19):2422-2427.
46. BORHANI NO, MERCURI M, BORHANI PA et al.: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA (1996) 276(10):785-791.
47. ZANCHETTI A, ROSEI EA, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A: The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J. Hypertens. (1998) 16(11):1667-1676.
48. ROSEI EA, DAL PALU C, LEONETTI G, MAGNANI B, PESSINA A, ZANCHETTI A: Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. VHAS Investigators. J. Hypertens. (1997) 15(11):1337-1344.
49. PITT B, BYINGTON RP, FURBERG CD et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation (2000) 102(13):1503-1510.
50. NISSEN SE, TUZCU EM, LIBBY P et al.: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA (2004) 292(18):2217-2225.
51. DEVEREUX RB, PALMIERI V, SHARPE N et al.: Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation (2001) 104(11):1248-1254.
52. DAHLÓF B, PENNERT K, HANSSON L: Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. (1992) 5(2):95-110.
53. CRUICKSHANK JM, LEWIS J, MOOREV, DODD C: Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. (1992) 6(2):85-90.
54. FAGARD RH: Reversibility of left ventricular hypertrophy by antihypertensive drugs. Neth. J. Med. (1995) 47(4):173-179.
55. BILGE AK, ATILGAN D, TUKEK T et al.: Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension. Int. J. Clin. Pract. (2005) 59(3):306-310.
56. LUKSA J, JOSIC D, PODOBNIK B, FURLAN B, KREMSER M: Semi-preparative Chromatographic purification of the enantiomers S-(-)-amlodipine and R-(+)-amlodipine. J. Chromatogr. B Biomed. Sci. Appl. (1997) 693(2):367-375.
57. FRISHMAN WH, ZUCKERMAN AL: Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. (2004) 2(5):675-681.
58. STIEBER J, HOFMANN F, LUDWIG A: Pacemaker channels and sinus node arrhythmia. Trends Cardiovasc. Med. (2004) 14(1):23-28.
59. 2+ channels. Lancet (2001) 357(9264):1294.
60. CABO C, SCHMITT H, WIT AL: New mechanism of antiarrhythmic drug action: increasing L-type calcium current prevents reentrant ventricular tachycardia in the infarcted canine heart. Circulation (2000) 102(19):2417-2425.
61. DRAZNER MH: The transition from hypertrophy to failure: how certain are we? Circulation (2005) 112(7):936-938.
62. NATHAN S, PEPINE CJ, BAKRIS GL: Calcium antagonists: effects on cardio-renal risk in hypertensive patients. Hypertension (2005) 46(4):637-642.
63. MOTZ W, STRAUER BE: Nifedipine in the long-term management of hypertensive heart disease. Hypertension (1983) 5(4 Pt 2):II39-II44.
64. CAMPBELL SE, TUREK Z, RAKUSAN K, KAZDA S: Cardiac structural remodelling after treatment of spontaneously hypertensive rats with nifedipine or nisoldipine. Cardiovasc. Res. (1993) 27(7):1350-1358.
65. KIM S, OHTA K, HAMAGUCHI A, YUKIMURA T, MIURA K, IWAO H: Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats. Br. J. Pharmacol. (1996) 118(3):549-556.
66. KYSELOVIC J, KRENEK P, WIBO M, GODFRAIND T: Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. Br. J. Pharmacol. (2001) 134(7):1516-1522.
67. SUSIC D, VARAGIC J, FROHLICH ED: Pharmacologic agents on cardiovascular mass, coronary dynamics and collagen in aged spontaneously hypertensive rats. J. Hypertens. (1999) 17(8):1209-1215.
68. NARUSE M, TANABE A, SEKI T et al.: Effects of two calcium channel blockers on messenger RNA expression of endothelin-1 and nitric oxide synthase in cardiovascular tissue of hypertensive rats. J. Hypertens. (1999) 17(1):53-60.
69. TAKAHASHI T, TANIKAWA S, TAKAHASHI K: Protective effects of CD-832 on organ damage in stroke-prone spontaneously hypertensive rats. Eur. J. Pharmacol. (1997) 331(2-3):193-198.
70. CARAFOLI E, BRINI M: Calcium pumps: structural basis for and mechanism of calcium transmembrane transport. Curr. Opin. Chem. Biol. (2000) 4(2):152-161.
71. BRINI M, CARAFOLI E: Calcium signalling: a historical account, recent developments and future perspectives. Cell Mol. Life Sci. (2000) 57(3):354-370.
72. 2+ pump isoforms in intact cells. J. Biol. Chem. (2003) 278(27):24500-24508.
73. BERRIDGE MJ, LIPP P, BOOTMAN MD: The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. (2000) 1(1):11-21.
74. 2+) signals. J. Cell Sci. (2001) 114(Pt 12):2213-2222.
75. BERRIDGE MJ, LIPP P, BOOTMAN MD: Signal transduction. The calcium entry pas de deux. Science (2000) 287(5458):1604-1605.
76. PETERSEN OH, BURDAKOV D, TEPIKIN AV: Polarity in intracellular calcium signaling. Bioessays (1999) 2l(10):851-860.
77. 2+) stores? Trends Neurosci. (2001) 24(5):271-276.
78. MOLKENTIN JD, DORN IG 2nd: Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Ann. Rev. Physiol. (2001) 63:391-426.
79. FREY N, MCKINSEY TA, OLSON EN: Decoding calcium signals involved in cardiac growth and function. Nat. Med. (2000) 6(11):1221-1227.
80. 2+ control of transcription: can we extrapolate signaling cascades from neurons to vascular smooth muscle cells? Circ. Res. (2004) 94(10):1276-1278.
81. WILKINS BJ, MOLKENTIN JD: Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. (2004) 322(4):1178-1191.
82. WILKINS BJ, DAI YS, BUENO OF et al.: Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. (2004) 94(1):110-118.
83. GODFRAIND T: Calcium antagonists and vasodilatation. Pharmacol. Ther. (1994) 64(1):37-75.
84. ++ entry blockers. A comparison of their actions in rat arteries and in human coronary arteries. Circ. Res. (1983) 52(2Pt2):I81-I91.
85. GODFRAIND T: Cardioselectivity of calcium antagonists. Cardiovasc. Drugs Ther. (1994) 8(Suppl. 2):353-364.
86. GODFRAIND T, SALOMONE S, DESSY C, VERHELST B, DION R, SCHOEVAERTS JC: Selectivity scale of calcium antagonists in the human cardiovascular system based on in vitro studies. J. Cardiovasc. Pharmacol. (1992) 20(Suppl. 5):S34-S4l.
87. SARSERO D, FUJIWARA T, MOLENAAR P, ANGUS JA: Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists. Br. J. Pharmacol. (1998) 125(1):109-119.
88. GODFRAIND T: Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries. J. Pharmacol. Exp. Ther. (1983) 224(2):443-450.
89. 1-subunits. Br. J. Pharmacol. (1998) 125(5):1005-1012.
90. DE PAOLI P, CERBAI E, KOIDL B, KIRCHENGAST M, SARTIANI L, MUGELLI A: selectivity of different calcium antagonists on T- and L-type calcium currents in guinea-pig ventricular myocytes. Pharmacol. Res. (2002) 46(6):491-497.
91. 2+ channels by amlodipine. Br. J. Pharmacol. (1997) 121(6):1136-1140.
92. BÉNARDEAU A, ERTEL EA: Selective block of myocardial T-type calcium channels by mibefradil: a comparison with the 1,4-dihydropyridine amlodipine. In: Low-voltage-activated t-type Ca channels. RW Tsien, JP Clozel, J Nargeot (Eds), Adis International, Chester, UK (1998):386-394.
93. XU B, XIAO-HONG L, LIN G, QUEEN L, FERRO A: Amlodipine, but not verapamil or nifedipine, dilates rabbit femoral artery largely through a nitric oxide- and kinin-dependent mechanism. Br. J. Pharmacol. (2002) 136(3):375-382.
94. GODFRAIND T, SALOMONE S: Calcium antagonists and endothelial function: focus on nitric oxide and endothelin. Cardiovasc. Drugs Ther. (1996) 10(4):439-446.
95. SALOMONE S, SILVA CL, MOREL N, GODFRAIND T: Facilitation of the vasorelaxant action of calcium antagonists by basal nitric oxide in depolarized artery. Naunyn Schmiedebergs Arch. Pharmacol. (1996) 354(4):505-512.
96. 2+ channels. Eur. J. Pharmacol. (1999) 373(1):93-100.
97. 2+ channels. Circ. Res. (1997) 81(4):526-532.
98. YATANI A, KUNZE DL, BROWN AM: Effects of dihydropyridine calcium channel modulators on cardiac sodium channels. Am. J. Physiol. (1988) 254(1 Pt2):H140-H147.
99. +-ATPase in catecholamine storage vesicles. Neuropharmacology (1999) 38(6):879-882.
100. GRACE AA, CAMM AJ: Voltage-gated calcium-channels and antiarrhythmic drug action. Cardiovasc. Res. (2000) 45(1):43-51.
101. +) channels expressed in HEK293 cells. Br. J. Pharmacol. (2003) 139(3):533-544.
102. BECKER RH, LINZ W, WIEMER G, NORDLANDER M: Low-dose felodipine treatment attenuates endothelial dysfunction in rabbits fed an atherogenic diet. J. Cardiovasc. Pharmacol. (1991) 18(Suppl. 10):S36-S41.
103. HABIB J, BOSSALLER C, WELLS S, WILLIAMS C, MORRISETT J, HENRY P: Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN-200110. Circ. Res. (1986) 58:305-309.
104. MONCADA S, MARTIN JF, HIGGS A: Symposium on regression of atherosclerosis. Eur. J. Clin. Invest. (1993) 23(7):385-398.
105. MONCADA S, HIGGS A: The L-arginine-nitric oxide pathway. N. Engl. J. Med. (1993) 329(27):2002-2012.
106. BROVKOVYCH VV, KALINOWSKI L, MULLER-PEDDINGHAUS R, MALINSKI T: Synergistic antihypertensive effects of nifedipine on endothelium: concurrent release of NO and scavenging of superoxide. Hypertension (2001) 37(1):34-39.
107. ZHANG X, HINTZE TH: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation (1998) 97(6):576-580.
108. ZHANG XP, LOKE KE, MITAL S, CHAHWALA S, HINTZE TH: Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J. Cardiovasc. Pharmacol. (2002) 39(2):208-214.
109. ZHANG X, RECCHIA FA, BERNSTEIN R, XU X, NASJLETTI A, HINTZE TH: Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure. J. Pharmacol. Exp. Ther. (1999) 288(2):742-751.
110. ZHANG X, KICHUK MR, MITAL S et al.: Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts. Am. J. Cardiol. (1999) 84(4A):27L-33L.
111. DING Y, VAZIRI ND: Calcium channel blockade enhances nitric oxide synthase expression by cultured endothelial cells. Hypertension (1998) 32(4):718-723.
112. WANG XQ, VAZIRI ND: Erythropoietin depresses nitric oxide synthase expression by human endothelial cells. Hypertension (1999) 33(3):894-899.
113. KRENEK P, SALOMONE S, KYSELOVIC J, WIBO M, MOREL N, GODFRAIND T: Lacidipine prevents endothelial dysfunction in salt-loaded stroke-prone hypertensive rats. Hypertension (2001) 37(4):1124-1128.
114. TADDEI S, VIRDIS A, GHIADONI L et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37(3):943-948.
115. TADDEI S, VIRDIS A, GHIADONI L et al.: Effect of calcium antagonist or β-blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens. (2001) 19(8):1379-1386.
116. NAPOLI C, CHIARIELLO M, PALUMBO G, AMBROSIO G: Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals. Cardiovasc. Drugs Ther. (1996) 10(4):417-424.
117. ROJSTACZER N, TRIGGLE DJ: Structure-function relationships of calcium antagonists. Effect on oxidative modification of low density lipoprotein. Biochem. Pharmacol. (1996) 51(2):141-150.
118. SOBALA G, MENZEL EJ, SINZINGER H: Calcium antagonists as inhibitors of in vitro low density lipoprotein oxidation and glycation. Biochem. Pharmacol. (2001) 61(3):373-379.
119. ZALBA G, SANJOSE G, MORENO MU et al.: Oxidative stress in arterial hypertension: role of NAD(P)H oxidase. Hypertension (2001) 38(6):1395-1399.
120. NAKAZONO K, WATANABE N, MATSUNO K, SASAKI J, SATO T, INOUE M: Does superoxide underlie the pathogenesis of hypertension? Proc. Natl. Acad. Sci. USA (1991) 88(22):10045-10048.
121. GRIENDLING KK, SORESCU D, USHIO-FUKAI M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. (2000) 86(5):494-501.
122. TOIKKA JO, LAINE H, AHOTUPA M et al.: Increased arterial intima-media thickness and in vivo LDL oxidation in young men with borderline hypertension. Hypertension (2000) 36(6):929-933.
123. IRANI K: Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. (2000) 87(3):179-183.
124. BRASIER AR, LI J: Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension (1996) 27(3 Pt 2):465-475.
125. LUFT FC: Angiotensin, inflammation, hypertension and cardiovascular disease. Curr. Hypertens. Rep. (2001) 3(1):61-67.
126. LUFT FC: Workshop: mechanisms and cardiovascular damage in hypertension. Hypertension (2001) 37(2 Part 2):594-598.
127. MASON RP: Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis (2002) 165(2):191-199.
128. URSINI F: Tissue protection by lacidipine: insight from redox behavior. J. Cardiovasc. Pharmacol. (1997) 30(Suppl. 2):S28-S30.
129. NAPOLI C, SALOMONE S, GODFRAIND T et al.: 1,4-Dihydropyridine calcium channel blockers inhibit plasma and LDL oxidation and formation of oxidation-specific epitopes in the arterial wall and prolong survival in stroke-prone spontaneously hypertensive rats. Stroke (1999) 30(9):1907-1915.
130. BERKELS R, EGINK G, MARSEN TA, BARTELS H, ROESEN R, KLAUS W: Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension (2001) 37(2):240-245.
131. COMINACINI L, GARBIN U, FRATTA PASINI A et al.: Lacidipine inhibits the activation of the transcription factor NF-κB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J. Hypertens. (1997) 15(12 Pt 2):1633-1640.
132. CRISTOFORI P, LANZONI A, QUARTAROLI M et al.: The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse. J. Hypertens. (2000) 18(10):1429-1436.
133. LEONETTI G, CUSPIDI C, SAMPIERI L, TERZOLI L, ZANCHETTI A: Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects. J. Cardiovasc. Pharmacol. (1982) 4(Suppl 3):S319-S324.
134. KNORR A, GARTHOFF B: Differential influence of the calcium antagonist nitrendipine and the vasodilator hydralazine on normal and elevated blood pressure. Arch. Int. Pharmacodyn. Ther. (1984) 269(2):316-322.
135. MOREL N, GODFRAIND T: Selective interaction of the calcium antagonist amlodipine with calcium channels in arteries of spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. (1994) 24(4):524-533.
136. + channels in aorta of hypertensive rats. Hypertension (1997) 30(6):1403-1409.
137. + channels in arteries from young spontaneously hypertensive rats. Eur. J. Pharmacol. (1993) 247(3):295-304.
138. COX RH, RUSCH NJ: New expression profiles of voltage-gated ion channels in arteries exposed to high blood pressure. Microcirculation (2002) 9(4):243-257.
139. + channels in resting state of femoral arteries from spontaneously hypertensive rats at prehypertensive stage. J. Pharmacol. Exp. Ther. (1995) 275(2):775-783.
140. JACKSON WF: Ion channels and vascular tone. Hypertension (2000) 35(1 Pt2):173-178.
141. 2+ channels in mesenteric and skeletal arteries of SHR. Hypertension (2002) 40(2):214-219.
142. MESSERLI F, SCHMIEDER RE, WEIR MR: Salt. A perpetrator of hypertensive target organ disease? Arch. Intern. Med. (1997) 157:2449-2452.
143. KYSELOVIC J, MOREL N, WIBO M, GODFRAIND T: Prevention of salt-dependent cardiac remodeling and enhanced gene expression in stroke-prone hypertensive rats by the long-acting calcium channel blocker lacidipine. J. Hypertens. (1998) 16(10):1515-1522.
144. ARRIBAS SM, COSTA R, SALOMONE S, MOREL N, GODFRAIND T, MCGRATH JC: Functional reduction and associated cellular rearrangement in SHRSP rat basilar arteries are affected by salt load and calcium antagonist treatment. J. Cereb. Blood Flow Metab. (1999) 19(5):517-527.
145. GODFRAIND T, SALOMONE S, MOREL N, GHISDAL P: [Preclinical study of the action of a calcium channel blocket during salt load]. Bull. Acad. Natl. Med. (1997) 181(2):289-298; discussion 299-300.
146. 2+ channel activator evoked by salt-loading in basilar artery of stroke-prone spontaneously hypertensive rats. Life Sci. (1996) 59(16):PL247-PL253.
147. HENRY PD: Atherogenesis, calcium and calcium antagonists. Am. J. Cardiol. (1990) 66(21):3I-6I.
148. TULENKO TN, SUMNER AE, CHEN M, HUANG Y, LAURY-KLEINTOP L, FERDINAND FD: The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am. Heart J. (2001) 141(2 Suppl.):S1-S11.
149. HANSSON GK, EDFELDT K: Toll to be paid at the gateway to the vessel wall. Arterioscler. Thromb. Vasc. Biol. (2005) 25(6):1085-1087.
150. DZAU VJ, BRAUN-DULLAEUS RC, SEDDING DG: Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat. Med. (2002) 8(11):1249-1256.
151. LIBBY P: Molecular bases of the acute coronary syndrome. Circulation (1995) 91:2844-2850.
152. HENRY P: Atherosclerosis, calcium and calcium antagonists. Circulation (1985) 72:456-459.
153. PAOLETTI R, CORSINI A, SOMA MR, BERNINI F: Calcium, calcium antagonists and experimental atherosclerosis. Blood Press. Suppl. (1996) 4:12-15.
154. SOMA MR, DONETTI E, PAROLINI C et al.: Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury. J. Cardiovasc. Pharmacol. (1994) 23(Suppl. 5):S71-S74.
155. SOMA MR, DONETTI E, SEREGNI R et al.: Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br. J. Pharmacol. (1996) 118(2):215-219.
156. DONETTI E, FUMAGALLI R, PAOLETTI R, SOMA MR: Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits. Pharmacol. Res. (1997) 35(5):417-422.
157. WILLIS AL, NAGEL B, CHURCHILL V et al.: Antiatherosclerotic effects of nicardipine and nifedipine in cholesterol-fed rabbits. Arteriosclerosis (1985) 5(3):250-255.
158. LICHTOR T, DAVIS HR, VESSELINOVITCH D, WISSLER RW, MULLAN S: Suppression of atherogenesis by nifedipine in the cholesterol-fed rhesus monkey. Appl. Pathol. (1989) 7(1):8-18.
159. BOSSALLER C, HABIB GB, YAMAMOTO H, WILLIAMS C, WELLS S, HENRY PD: Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J. Clin. Invest. (1987) 79(1):170-174.
160. HABIB JB, BOSSALLER C, WELLS S, WILLIAMS C, MORRISETT JD, HENRY PD: Preservation of endothelium-dependent vascular relaxation in cholesterol-fed rabbit by treatment with the calcium blocker PN 200110. Circ. Res. (1986) 58(2):305-309.
161. PRATICO D, TANGIRALA RK, RADER DJ, ROKACH J, FITZGERALD GA: Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. (1998) 4(10):1189-1192.
162. THOMAS SR, LEICHTWEIS SB, PETTERSSON K et al.: Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler. Thromb. Vasc. Biol. (2001) 21(4):585-593.
163. NAKASHIMA Y, PLUMP AS, RAINES EW, BRESLOW JL, ROSS R: ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. (1994) 14:133-140.
164. BARTON M, HAUDENSCHILD CC, D'USCIO LV, SHAW S, MUNTER K, LUSCHER TF: Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95(24):14367-14372.
165. D'USCIO LV, BAKER TA, MANTILLA CB et al.: Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. (2001) 21(6):1017-1022.
166. PLUMP AS, SMITH JD, HAYEK T et al.: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell (1992) 71(2):343-353.
167. BONTHU S, HEISTAD DD, CHAPPELL DA, LAMPING KG, FARACI FM: Atherosclerosis, vascular remodeling, and impairment of endothelium-dependent relaxation in genetically altered hyperlipidemic mice. Arterioscler. Thromb. Vasc. Biol. (1997) 17(11):2333-2340.
168. BARTON M, HAUDENSCHILD CC: Endothelium and atherogenesis: endothelial therapy revisited. J. Cardiovasc. Pharmacol. (2001) 38(Suppl. 2):S23-S25.
169. LIBBY P, GALIS ZS: Cytokines regulate genes involved in atherogenesis. Ann. NY Acad. Sci. (1995) 748:158-168; discussion 168-170.
170. LIBBY P, SUKHOVA G, LEE RT, GALIS ZS: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol. (1995) 25(Suppl. 2):S9-S12.
171. HAYEK T, OIKNINE J, BROOK JG, AVIRAM M: Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochem. Biophys. Res. Commun. (1994) 201(3):1567-1574.
172. JIANG F, GIBSON AP, DUSTING GJ: Endothelial dysfunction induced by oxidized low-density lipoproteins in isolated mouse aorta: a comparison with apolipoprotein-E deficient mice. Eur. J. Pharmacol. (2001) 424(2):141-149.
173. LU X, KASSAB GS: Nitric oxide is significantly reduced in ex-vivo porcine arteries during reverse flow because of increased superoxide production. J. Physiol. (2004) 561(Pt2):575-582.
174. KYSELOVIC J, MARTINKA P, BATOVA Z, GAZOVA A, GODFRAIND T: Calcium channel blocker inhibits western-type diet-evoked atherosclerosis development in ApoE-deficient mice. J. Pharmacol. Exp. Ther. (2005) 315(1):320-328.
175. UNEYAMA H, UCHIDA H, KONDA T, YOSIMOTO R: Cilnidipine: preclinical
176. POOLE-WILSON PA, LUBSEN J, KIRWAN BA et al.: Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet (2004) 364(9437):849-857.
177. NORDLANDER M, SJOQUIST PO, ERICSSON H, RYDEN L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. (2004) 22(3):227-250.
178. LIANG JC, YEH JL, WANG CS, LIOU SF, TSAI CH, CHEN IJ: The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display α-/β-adrenoceptor antagonist and long-acting antihypertensive activities. Bioorg. Med. Chem. (2002) 10(3):719-730.
179. LIOU SF, YEH JL, LIANG JC, CHIU CC, LIN YT, CHEN IJ: Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J. Cardiovasc. Pharmacol. (2004) 44(5):539-551.
180. SHAN R, VELAZQUEZ C, KNAUS EE: Syntheses, calcium channel agonist-antagonist modulation activities, and nitric oxide release studies of nitrooxyalkyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl) pyridine-5-carboxylate racemates, enantiomers, and diastereomers. J. Med. Chem. (2004) 47(1):254-261.
181. GORDEEV MF, PATEL DV, ENGLAND BP, JONNALAGADDA S, COMBS JD, GORDON EM: Combinatorial synthesis and screening of a chemical library of 1,4-dihydropyridine calcium channel blockers. Bioorg. Med. Chem. (1998) 6(7):883-889.
182. WILLUMSEN NJ, BECH M, OLESEN SP, JENSEN BS, KORSGAARD MP, CHRISTOPHERSEN P: High throughput electrophysiology: new perspectives for ion channel drug discovery. Receptors Channels (2003) 9(1):3-12.
183. CARD GL, BLASDEL L, ENGLAND BP et al.: A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat. Biotechnol. (2005) 23(2):201-207.
184. + currents by nisoldipine. Br. J. Pharmacol. (2003) 140(5):863-870.
185. +) currents in guinea-pig ventricular myocytes. Br. J. Pharmacol. (2000) 131(8):1809-1816.
186. +) currents by nifedipine. Eur. J. Pharmacol. (2000) 401(2):137-143.
187. 3H]prazosin to porcine aortic membranes: interaction of calcium antagonists with vascular α-1 adrenoceptors. J. Pharmacol. Exp. Ther. (1986) 236(3):789-793.
188. ROGER S, LE GUENNEC JY, BESSON P: Particular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breast cancer cell line. Br. J. Pharmacol. (2004) 141(4):610-615.
189. GODFRAIND T, KABA A: Blockade or reversal of the contraction induced by calcium and adrenaline in depolarized arterial smooth muscle. Br. J. Pharmacol. (1969) 36(3):549-560.
190. JAMERSON KA, BAKRIS GL, WUN CC et al.: Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am. J. Hypertens. (2004) 17(9):793-801.
191. SEVER PS, DAHLÖF B, POULTER NR et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 361(9364):1149-1158.
192. DAHLÖF B, SEVER PS, POULTER NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 366(9489):895-906.
193. ENCORE INVESTIGATORS: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation (2003) 107(3):422-428.
194. BROWN MJ, PALMER CR, CASTAIGNE A et al.: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet (2000) 356(9227):366-372.
195. PEPINE CJ, HANDBERG EM, COOPER-DEHOFF RM et al.: A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA (2003) 290(21):2805-2816.
196. SCHRADER J, LUDERS S, KULSCHEWSKI A et al.: Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke (2005) 36(6):1218-1226.
197. DENS JA, DESMET WJ, COUSSEMENT P et al.: Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study. Heart (2003) 89(8):887-892.
198. HANSSON L, HEDNER T, LUNDHJOHANSEN P et al.: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet (2000) 356(9227):359-365.
199. MALACCO E, MANCIA G, RAPPELLI A, MENOTTI A, ZUCCARO MS, COPPINI A: Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. (2003) 12(3):160-167.
200. GONG L, ZHANG W, ZHU Y et al.: Shanghai trial of nifedipine in the elderly (STONE). J. Hypertens. (1996) 14(10):1237-1245.
201. WANG JG, LIU G, WANG X et al.: Long-term blood pressure control in older Chinese patients with isolated systolic hypertension: a progress report on the Syst-China trial. J. Hum. Hypertens. (1996) 10(11):735-742.
202. STAESSEN JA, FAGARD R, THIJS L et al.: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet (1997) 350(9080):757-764.
203. JULIUS S, KJELDSEN SE, BRUNNER H et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. (2003) 16(7):544-548.